COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit is an In Vitro Diagnostic (IVD) reagent replying on fluorescent PCR technology and aiming at qualitatively detection and differentiation of human RNA from SARS-CoV-2 from upper and lower respiratory tract samples. Primer and probe are selected fromOpen Reading Framegene region (ORF1a/b),envelope protein (E)andnucleocapsid region (N)for SARS-CoV-2. The kit is a multiplex assay, run in a single well/vessel, designed for detection and differenti

In October 2020, SARS-CoV-2 lineage B.1.617 emerged in India, causing an exponential increase in COVID-19 cases across the country. The lineage is further divided into three subgroups: B.1.617.1, B.1.617.2, and B.1.617.3, of which the B.1.617.2 variant (also known as Delta variant) has been designated as Variant of Concern (VOC) by WHO because of significantly increased infectivity. The mutations L452R and E484Q, along with P681R in the furin cleavage site are reported to lead to increased ACE

SARS-CoV-2 Lambda (C.37) variant was first detected in Peru in December 2020 and has been designated as a VOI by the WHO in June 2021, due to a heightened presence of this variant in Peru, Chile, United States of America, Argentina, etc.The spike protein of the Lambda variant is more infectious, which is attributed to the T76I and L452Q mutations. Another mutation F490S has already been associated with reduced susceptibility to antibodies generated in patients who had recovered from COVID. Thi

On Nov. 24, 2021, the variant B.1.1.529 was first identified in South Africa, and only two days later, WHO announced that B.1.1.529 constitutes a variant of concern, named Omicron. There are more than 30 mutation sites on the S gene of variant B.1.1.529. Omicron has a greater binding affinity than the original SARS-CoV-2 virus, with levels more comparable to what we see with the Delta variant. Some of the mutations have been detected in previous variants, such as Alpha and Delta, and have been

The Bioperfectus Technologies Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) is a lateral flow test intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. Fast: results within 15 minutesEasy to use: prepacked design makes testing more convenientHumanized: all neces

The Bioperfectus Technologies Novel Corona Virus（SARS-CoV-2）Ag Rapid Test Kit including Prepacked Extraction Tube is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swabs from individuals who are suspected of COVID-19 within the first seven days of the onset of symptoms. Fast: results within 15 minutesEasy to use: prepacked design makes testing more convenientHumanized: all necessary components providedFlexible: different

The Novel Corona Virus（SARS-CoV-2）IgM/IgG Rapid Test Kit from Bioperfectus is an in vitro diagnostic test used for the detection of novel coronavirus (SARS-CoV-2) IgM and IgG antibodies.This product is based on immunochromatographic technology. The detection area of the strip has an IgM test line (T2 line), an IgG test line (T1 line) and a control line (C line). Fast results within 10-15 minutesEasy to use: 3 steps to finish the testQuality control: ensure the result is reliableMultiple ant